Guggenheim analyst Brad Canino maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises

Wells Fargo analyst Derek Archila maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight a

Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 d

Barclays analyst Eliana Merle maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and r

Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript

Kymera Therapeutics NASDAQ: KYMR said it completed enrollment in its Phase 2b atopic dermatitis tria

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.62 per share versus the Zacks

Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.62) per share which beat the anal

Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticip

Top Wall Street analysts changed their outlook on various stocks. Check out the analyst ratings page

Wall Street analysts reshuffled their bets on Thursday as geopolitical fires, a Fed dissent surprise

Deutsche Bank analyst David Hoang initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a

WATERTOWN, Mass. , July 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a cli

Guggenheim analyst Brad Canino maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises

Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy a

NEW YORK, July 27, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves

Kymera Therapeutics, Inc. (NASDAQ: KYMR - Get Free Report) gapped up before the market opened on Fri

Kymera Therapeutics advances KT-621 enrollment ahead of schedule, bringing pivotal atopic dermatitis

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is i

SHAREHOLDER ALERT: Purcell and Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeut

NEW YORK, July 16, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating K

Mizuho analyst Joseph Catanzaro maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and

RBC Capital analyst Brian Abrahams downgrades Kymera Therapeutics (NASDAQ:KYMR) from Outperform t

According to a Form 4, proceeds of approximately $6.0 million were realized from the exercise and im

Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 pro

Kymera Therapeutics (KYMR) is upgraded to Buy, driven by strong pipeline progress and a robust $1.5b

Kymera Therapeutics is rated Buy ahead of the 2H26 KT-621 Phase 2b readout, seen as a key inflection

B of A Securities analyst Tazeen Ahmad maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and

Truist Securities analyst Srikripa Devarakonda maintains Kymera Therapeutics (NASDAQ:KYMR) with a

B. Riley Securities analyst Kalpit Patel maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy a

Canaccord Genuity analyst Edward Nash maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and

Kymera Therapeutics shares surged after completing KT-621 Phase 2b enrollment early, accelerating da

BTIG analyst Jeet Mukherjee reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and maintain

U.S. stocks traded mostly higher, with the Nasdaq Composite down 0.1%. Industrials jumped 2.5%, whil

Dow Jones index gained 200 points; Acuity Inc (NYSE: AYI) reported better-than-expected financial re

BROADEN2 enrollment completed nearly six months ahead of anticipated timelinesKT-621 Phase 3 trials

Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new

U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Thera

"The consistency we've demonstrated across KT-621 Phase 1 studies, from robust STAT6 degrada

First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million miles

KT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and cli

Society for Investigative Dermatology (SID) 2026 Annual MeetingTitle: KT-621 Treatment Induces Rapid

Canaccord Genuity analyst Edward Nash initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) wit

The Company previously reported data demonstrating KT-579's compelling profile in preclinical st

Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.71) per share which beat the anal

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027KT-621 B

Gilead expands Tempus AI deal and licenses Kymera's KT-200, advancing oncology pipeline with dat

KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate Option exercise

US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen